MedImmune to Present 11 Abstracts on Influenza at 45th Annual National Immunization Conference

WASHINGTON, March 29, 2011 /PRNewswire/ -- MedImmune announced today it will present a total of 11 abstracts at the 45th National Immunization Conference (NIC) at the Washington Hilton in Washington, DC, March 28 - 31, 2011.  These abstracts advance the body of existing data and knowledge surrounding influenza prevention and trends in vaccination, highlighting MedImmune's strong leadership in patient health in various medical settings.

"MedImmune is pleased to announce new research on school-located influenza vaccination programs and use of influenza vaccines in special populations," said William Martone, MD, senior vice president of medical and scientific affairs at MedImmune. "We believe the data being presented at NIC will help the medical community explore innovative ways to prevent influenza in and outside of the medical home."

MedImmune abstracts to be presented at NIC on school-located influenza vaccination programs include:

  • Factors Associated with Increased Vaccination In 2009 H1N1 School-Located Influenza Vaccination Programs. Ambrose CS, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25171
  • The Impact of School-Located Influenza Vaccination Programs on Student Absenteeism: A Review of the US Literature. Hull, HF, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25129
  • Current Experience with School-Located Influenza Vaccination Programs in the United States:  A Review of the Medical Literature. Hull, HF, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25160

MedImmune abstracts to be presented at NIC on influenza vaccines in specific populations and/or groups include:

  • A Post-Licensure Evaluation of the Safety of Live Attenuated Influenza Vaccine in Individuals 5 to 49 Years of Age. Toback, SL, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25173
  • A Postmarketing Evaluation of the Frequency of Use and Safety of Live Attenuated Influenza Vaccine in Non-Recommended Children Less Than 60 Months of Age. Toback, SL, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25166
  • Factors Associated with Increased In-Office Influenza Vaccine Coverage and Two-Dose Compliance Among U.S. Pediatricians. Toback, SL, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25177
  • Influenza Vaccination Attitudes and Beliefs Among U.S. Working Adults Attending Employer-Based Vaccination Clinics. Toback, SL, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25163
  • Maternal Outcomes in Pregnant Women Receiving Live Attenuated Influenza Vaccine. Toback, SL, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25172
  • Real-Time Assessment of the 2010-2011 Pediatric Influenza Vaccination Season. Toback SL, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25176
  • Trends in U.S. Pediatric Influenza Vaccination from 2006 to 2010. Toback, SL, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25161
  • U.S. Pediatric Influenza Vaccination by Pediatricians and Family Physicians From 2006 to 2010. Toback, SL, et al. Poster Session: March 29, 2011 Time: 10 - 11 AM, 3 - 4 PM; Columbia Hall, Poster # 25174

Additional information about the 2011 NIC conference can be found at http://www.cdc.gov/vaccines/events/nic/default.htm.

About MedImmune

MedImmune, the global biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,500 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising drug candidates, MedImmune strives to deliver life-changing products, a rewarding career to our employees and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com.

SOURCE MedImmune

CONTACT: Media: Melissa Garcia, +1-301-398-6470, garciame@MedImmune.com

Web Site: http://www.medimmune.com
 

 

 
 

Posted: March 2011

View comments

Hide
(web2)